Published in Lancet Oncol on February 13, 2013
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | NCT01320085
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA (2014) 2.48
MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist (2014) 1.71
NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol (2013) 1.63
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood (2014) 1.60
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med (2016) 1.52
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One (2016) 1.41
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol (2014) 1.11
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res (2015) 1.08
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget (2015) 1.06
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics (2014) 1.00
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer (2014) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med (2013) 0.98
Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Mol Diagn Ther (2015) 0.98
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res (2014) 0.98
BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res (2014) 0.94
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest (2014) 0.94
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer (2015) 0.93
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discov (2017) 0.92
Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91
Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway. Neuro Oncol (2015) 0.91
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med (2016) 0.90
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene (2015) 0.90
Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun (2014) 0.90
Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis (2013) 0.90
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer (2013) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res (2014) 0.88
Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nat Med (2013) 0.87
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer (2015) 0.87
NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol (2015) 0.87
Small molecule drugs with immunomodulatory effects in cancer. Hum Vaccin Immunother (2015) 0.86
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget (2015) 0.85
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett (2015) 0.85
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol (2015) 0.85
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res (2014) 0.85
Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations. EJC Suppl (2013) 0.85
Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) (2013) 0.85
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol (2015) 0.84
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med (2014) 0.84
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A (2016) 0.84
Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget (2015) 0.83
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol (2016) 0.83
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer (2015) 0.82
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics (2014) 0.82
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities. Mol Cancer Ther (2016) 0.81
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol (2014) 0.81
Novel targets for the treatment of ameloblastoma. J Dent Res (2014) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep (2013) 0.80
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol (2014) 0.79
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol (2013) 0.78
Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncol (2013) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis. BMC Cancer (2015) 0.78
Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther (2015) 0.78
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med (2015) 0.77
Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment? Front Med (Lausanne) (2014) 0.77
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res (2014) 0.77
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol (2016) 0.77
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget (2017) 0.76
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs (2016) 0.76
Targeted therapies in melanoma. Surg Oncol Clin N Am (2015) 0.76
Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget (2015) 0.76
Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. BMC Genomics (2016) 0.76
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol (2015) 0.76
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol (2015) 0.76
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer (2016) 0.76
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep (2015) 0.76
Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr (2015) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget (2015) 0.76
Therapeutic Approaches to RAS Mutation. Cancer J (2016) 0.76
The NF1 gene in tumor syndromes and melanoma. Lab Invest (2017) 0.75
Melanoma driver mutations and immune therapy. Oncoimmunology (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum (2007) 3.22
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell (2005) 3.12
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol (2010) 2.16
Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res (2008) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother (2004) 2.12
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96